Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebif New Formulation in High Risk MS (REFLEX)
NCT00404352Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2006
- Primary completion
- Aug 2010
- Modality
- Cytokines & Interferons
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of interferon beta-1a in clinically isolated syndrome (CIS) (3 arms), sponsored by Merck KGaA. Primary endpoint: Time to Conversion to Multiple Sclerosis According to the McDonald Criteria (2005) at 24 months. Started Nov 2006; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT00404352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00404352.